PSY72 AN EUROPEAN OVERVIEW OF THE FUTURE CHANGES IN EVIDENCE REQUIREMENTS FOR THE REIMBURSEMENT OF ORPHAN DRUGS-A STAKEHOLDER ANALYSIS  by Krueger, L.J. et al.
A236  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
focused around more scrutiny in the reimbursement assessment of orphan 
drugs. ConClusions: All twenty stakeholders gave recommendations about a 
stronger European cooperation for the value assessment of orphan drugs, with 
eleven stakeholders suggesting a European reimbursement system for orphan 
drugs.
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objeCtives: Reimbursement processes have been implemented to inform which 
therapies should be funded in light of scarce health care resources. However, the 
applicability of standard processes to drugs for rare diseases is heavily debated. As 
a result of the small patient populations affected by rare diseases, coupled with a 
limited understanding of the natural history of these conditions and the high cost of 
these treatments, it is argued that drugs for rare diseases may not meet the eviden-
tiary standards routinely applied when making resource allocation decisions. This 
study identified current reimbursement processes for prescription pharmaceuticals 
both within Canada and internationally, with the objective of assessing how drugs 
for rare diseases are considered within existing processes. Methods: Using the 
G20 countries as a sampling frame, a review of published and grey literature was 
conducted to identify the reimbursement processes used in 28 countries, and in 
Canadian provinces/territories. A search for peer-reviewed publications was con-
ducted using Medline, Scopus, CINHAL, EconLit and PsychInfo. The grey literature 
search included websites of health technology assessment agencies and govern-
ment agencies. Results: Drugs for rare diseases are considering uniquely for reim-
bursement within three Canadian provinces and seven countries. Reimbursement 
frameworks focused specifically on the reimbursement of drugs for rare diseases 
are limited. In some jurisdictions, drugs for rare diseases are considered uniquely 
within the established decision-making process for drugs. Varying decision criteria 
are applied within the identified processes for the reimbursement of drugs for rare 
diseases. ConClusions: This review identifies approaches for making resource 
allocation decisions for drugs; explicitly considering funding decisions related to 
drugs for rare diseases. An understanding of these frameworks and the decision 
criteria applied when making resource allocation decisions may help inform the 
development of more standardized approaches for the reimbursement of drugs 
for rare diseases.
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objeCtives: To identify research studies that examine the economic and/or 
humanistic burden of R/R iNHL, and identify evidentiary gaps which could be 
informed by future research. Methods: iNHL refers to a group of largely incur-
able slow-growing lymphomas that run a relapsing course after therapy, and 
can lead ultimately to life-threatening complications. Although many thera-
pies are available, patients eventually relapse and become refractory to existing 
therapies. As such, additional treatment options with improved response rate, 
durability of response and more manageable toxicity are needed to treat patients 
with R/R iNHL. A structured literature search was performed to assess the eco-
nomic and patient burden of iNHL. English-language articles published since 
2009 were systematically reviewed in PubMed, EMBASE and Cochrane databases. 
Additionally, searches from global HTA organizations and conference abstracts 
were performed. Research was considered relevant to the economic and human-
istic burden of iNHL based on reported outcomes such as resource utilization, 
costs, or relevant patient-reported outcomes associated with relapsed/refractory 
iNHL. Results: Few cost-of-illness studies or HTAs address iNHL. Evidence was 
limited to hospital-based direct treatment costs, omitting societal and indirect 
costs of the disease. Multiple cost-effectiveness analyses were identified focusing 
on Rituximab; however, few studies evaluated the cost-effectiveness of alterna-
tive 2nd or 3rdline therapies in the case of R/R iNHL. The majority of identified 
patient reported outcomes (PRO) research exists as conference abstracts. No stud-
ies were identified that examine PRO in a R/R iNHL population. ConClusions: 
The economic and humanistic burden of R/R iNHL has not been widely reported 
in the literature. Areas of future research may include evaluating both direct 
and indirect costs in R/R iNHL. PROs are not well understood in iNHL, and future 
research should focus on QoL and related factors that may help evaluate any 
trade-off between progression-free survival and the severity/duration of adverse 
events.
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objeCtives: In context of Health Technology Assessment (HTA) decision frame-
work, some countries (e.g. Germany) have a special regulation for orphan drugs 
(OD), while others (e.g. France) don’t. The aim of the study was to compare the 
HTA decisions, prices and reimbursements for the OD that have been evaluated in 
France and Germany. Methods: We selected OD assessed under AMNOG law in 
Germany and reviewed HTA assessments from the Transparency Committee (TC) 
for France and from IGWiG/G-BA for Germany, and extracted prices and reimburse-
These analyses suggest that OXY access restrictions such as PA and TC did not 
result in cost savings.
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objeCtives: In 2006, the American College of Medical Genetics (ACMG) recom-
mended a significantly expanded group of rare conditions for state-based US 
NBS programs. Initial efforts to explore the implications of this expansion used 
national incidence data applied to the states due to an inability to gather current 
state-specific numbers. Older state-specific numbers were later identified. This 
research assesses the error associated with estimating consequences of these 
programs by using national vs. state-specific incidence estimates. Methods: We 
collected data on national disease incidence and state-specific numbers of births 
(2011), state-specific disease cases (2003 and 2006) and number of required NBS 
tests/birth and reported fees. We developed two estimates of cases: 1) expected 
cases by applying national incidence to current state births and 2) cases identified 
using state-specific actual observations (averaged over the 2 years and applied 
to current number of births). We also calculated the cost per expected identified 
case using both methods of estimating cases. Results: The differences in num-
bers based on state actuals vs. expected cases calculated from national incidence 
estimates was expressed as a percentage of the actuals. For CH this ranged from 
-71% to + 200% (mean= -33%; 46 were negative; 2 were positive; 3 unchanged) and 
in CAH from -67% to + 500% (mean= +70%; 9 were negative; 22 were positive; 7 
unchanged and 13 missing or undefined due to no cases being in the denominator 
of the calculation). Similar differences were observed in calculations of cost per 
identified cases. ConClusions: Sampling variation and the association with 
ethnicity and other differences by state demographics implied added variation 
in state actuals compared to national incidence used in predictions. The one-
sided error observed in the CH calculations leads us to question the accuracy of 
the national incidence figure. Application of national incidence to state-specific 
situations should proceed with caution.
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bACkgRound:: Obesity can be understood as a problem resulting from the imbal-
ance between the intake and the individual caloric expenditure, which has sparked 
concern among researchers and policymakers in public health. The alert comes 
up with the fast growth in the prevalence of obesity in adults and children in 
Brazil. objeCtives: In this context, the challenge of this essay is to analyze the 
major changes in BMI between 2002 and 2009 and to estimate the relationship 
between food prices and obesity, in order to check the effect of food prices on BMI 
in Brazil. Methods: To assess the changes in BMI over time, first of all, we analyze 
its distribution using the relative distribution method proposed by Handcock and 
Morris (1998). Then, recentered influence function (RIF) regressions were applied 
to decompose the changes in the BMI distribution into composition and struc-
ture effects and identify the specific contribution of food prices. The empirical 
estimates needed are based on micro-data from household budget survey in 
two points of time: 2002-2003 and 2008-2009 accomplished by the Brazilian 
Institute of geography (IBGE). Were considered only the information regarding 
the adult population aged less than 20 years. Results: The main changes in 
BMI distribution showed that the density has moved to the right over the time 
and there were increases in the right hand tail. Despite the small effect, the RIF 
results show that the prices variations over the period contributed to change BMI. 
If prices had not changed, the median BMI would be 0.22 higher. The increases in 
the prices of meat, ssb and fruits and vegetables showed the greatest mean effects 
on BMI, especially to upper quantiles of the distribution. There are also evidences 
that income and age contributed to rise BMI, while education is associated to a 
lowering effect.
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objeCtives: In 2000 the Orphan Drug Act was designed to supported drug devel-
opment for rare disease in Europe. Now thirteen years after the Act was passed, 
orphan drug development has immensely increased and health care systems 
are challenged to find more appropriate assessment mechanism for the reim-
bursement of orphan drugs. Public awareness has lately been raised by major 
discussions about the discontinuation of reimbursement for several orphan drugs. 
By conducting qualitative interviews this article aims to identify the view of dif-
ferent stakeholders about recent and future changes within the reimbursement 
assessment and its evidence requirements for orphan drugs. Methods: Twenty 
semi-structured interviews were conducted with relevant stakeholders from the 
orphan drug community. Interviewees were scientific experts, reimbursement 
agencies, industry and patient organizations from five European countries. The 
interviews were analyzed with the framework analysis technique. Results: 
All twenty stakeholders have reported about recent or future changes in their 
national reimbursement practice for orphan drugs. The most emerging theme 
